VCYT Insider Trading

Insider Ownership Percentage: 1.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $2,594,329.26

Veracyte Insider Trading History Chart

This chart shows the insider buying and selling history at Veracyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2M$0$2MTotal Insider BuyingTotal Insider Selling

Veracyte Share Price & Price History

Current Price: $31.19
Price Change: Price Decrease of -0.477 (-1.51%)
As of 04/29/2025 11:52 AM ET

This chart shows the closing price history over time for VCYT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$31.67Closing price on 04/28/25:

SEC Filings (Institutional Ownership Changes) for Veracyte (NASDAQ:VCYT)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at VCYT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$17Mbought$9.77MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1B-$500M$0$500M$1BTotal InflowsTotal Outflows
Veracyte logo
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Read More on Veracyte

Today's Range

Now: $31.19
Low: $31.10
High: $31.76

50 Day Range

MA: $32.04
Low: $28.47
High: $41.05

52 Week Range

Now: $31.19
Low: $19.48
High: $47.32

Volume

105,271 shs

Average Volume

930,555 shs

Market Capitalization

$2.43 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.03

Who are the company insiders with the largest holdings of Veracyte?

Veracyte's top insider shareholders include:
  1. Rebecca Chambers (CFO)
  2. John Leite (Insider)
  3. Evan/ Fa Jones (Director)
  4. Jonathan Wygant (CAO)
  5. Karin Eastham (Director)
  6. John L Bishop (Director)
  7. Muna Bhanji (Director)
  8. Jens Holstein (Director)
Learn More about top insider investors at Veracyte.

Who are the major institutional investors of Veracyte?

Veracyte's top institutional investors include:
  1. Sumitomo Mitsui Trust Group Inc. — 2.90%
  2. AEGON ASSET MANAGEMENT UK Plc — 0.84%
  3. Assenagon Asset Management S.A. — 0.63%
  4. Rhumbline Advisers — 0.15%
  5. Exchange Traded Concepts LLC — 0.12%
  6. AMI Asset Management Corp — 0.06%
Learn More about top institutional investors of Veracyte stock.

Which major investors are selling Veracyte stock?

In the last quarter, VCYT stock was sold by these institutional investors:
  1. Sumitomo Mitsui Trust Group Inc.
  2. Teacher Retirement System of Texas
  3. AEGON ASSET MANAGEMENT UK Plc
  4. Quent Capital LLC
  5. Diversified Trust Co
  6. Parallel Advisors LLC
  7. Rhumbline Advisers
  8. Avanza Fonder AB
In the previous year, company insiders that have sold Veracyte company stock include:
  1. Rebecca Chambers (CFO)
  2. John Leite (Insider)
  3. Evan/ Fa Jones (Director)
  4. Jonathan Wygant (CAO)
  5. Karin Eastham (Director)
  6. John L Bishop (Director)
  7. Muna Bhanji (Director)
Learn More investors selling Veracyte stock.

Which major investors are buying Veracyte stock?

During the last quarter, VCYT stock was bought by institutional investors including:
  1. Assenagon Asset Management S.A.
  2. Exchange Traded Concepts LLC
  3. GAMMA Investing LLC
  4. AMI Asset Management Corp
  5. Wealth Enhancement Advisory Services LLC
  6. Yorktown Management & Research Co Inc
  7. Allspring Global Investments Holdings LLC
  8. Principal Financial Group Inc.